삼성바이오로직스

207940KOSPI기초 의약물질 제조업

53.5 / 100

Reference Date: 2026-04-13

Financial Score15.5 / 40

News Sentiment13.0 / 25

Momentum11.0 / 20

Disclosure14.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Slightly down 1.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Samsung BioLogics is a global CDMO (Contract Development and Manufacturing Organization) providing biopharmaceutical contract manufacturing and development services. In 2025, it restructured into a pure-play CDMO business by spinning off Samsung Epics Holdings. The company generates significant revenue from Europe and the U.S. and is expanding into next-generation biopharmaceuticals such as mRNA, ADC, and cell/gene therapies.

Number of Employees

10,910people

Average Salary

114.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

40.76Industry Average 33.453.0Point

Higher than industry avg (caution)

PBR

9.76Industry Average 2.030.0Point

4.8x industry avg (risky)

ROE

19.44Industry Average -4.293.5Point

Well below industry avg

Debt Ratio

14.45Industry Average 6.610.0Point

2.2x industry avg (risky)

Trend 2023~20259.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲11.6% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲37.6% (2-year basis)

ROE Trend

3.5 / 4

Avg ROE 13.0% (improving, 3yr)

Detailed News Sentiment

89 totalPositive 15Neutral 64Negative 5Average Sentiment Score 52.3

Detailed Momentum

52-week position3.0Point

52w lower range (22%)

Current 1,571,000Won52-week high 1,965,00052-week low 1,458,498

1-month return3.0Point

1m -1.32% (flat)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

10 totalPositive 2Neutral 8Negative 0

Positive[기재정정]단일판매ㆍ공급계약체결2026-04-10
Neutral결산실적공시예고(안내공시)2026-04-08
Neutral최대주주등소유주식변동신고서2026-04-06
Neutral[기재정정]타법인주식및출자증권취득결정(자율공시)(종속회사의주요경영사항)2026-03-31
Neutral[기재정정]감사보고서제출2026-03-26